Sanofi Continues Hunt For External Innovation With Skyhawk Deal
Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.
Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.